MINERVA II Project

The MINERVA II project seeks to identify molecular alterations in patients with cardiorenal disease characterized by the presence of chronic heart failure (CHF) and chronic kidney disease (CKD) through a multi-omics approach.

This is the continuation of the public-private consortium that worked on the first phase, the MINERVA project, in which more than 700 patients were recruited. This consortium is made up of the Cima Universidad de Navarra, which coordinates the project, the Clínica Universidad de Navarra, Navarrabiomed, the Complejo Hospitalario de Navarra and the company NNBi 2020 S.L. The MINERVA II project aims to exploit and validate the information collected in the first phase to develop a new panel of biomarkers with diagnostic utility and to identify new targets with therapeutic potential.

The patients recruited will be followed up clinically for three years, which will make it possible to test the prognostic usefulness of these biomarkers through the application of specific "omics" technology.

The results of the project will provide the basis for the development of preventive therapeutic strategies for patients with cardiorenal disease. It is anticipated that these products will help specialists in the Navarra Health System (SNS) and the Autonomous Community as a whole to apply for personalized precision medicine in the context of cardiorenal disease. This project is aligned with the RIS3 strategy of Navarra and with the bases of the European Commission's Horizon Europe program.